Join the Hepatitis B group to help and get support from people like you.
Hepatitis B News
Related terms: Chronic Hepatitis B, Hepatitis B, Chronic, HBV
Dose-Dependent Link Seen for Alcohol, Cirrhosis, Liver Cancer in Patients With Hep B
WEDNESDAY, Jan. 29, 2025 – For patients with hepatitis B virus, alcohol is associated with dose-dependent increased risks for cirrhosis and hepatocellular carcinoma (HCC), according to a review...
Combo Treatment With Xalnesiran Shows Promise in Patients With Hep B
FRIDAY, Dec. 13, 2024 – For patients with chronic hepatitis B virus (HBV) infection with virologic suppression with nucleoside or nucleotide analog (NA) therapy, xalnesiran plus an immunomodulator...
Thousands of Hospital Patients in Oregon May Have Been Exposed to Hepatitis, HIV
FRIDAY, July 12, 2024 – After an anesthesiologist may have exposed thousands of people treated at several hospitals in Oregon to hepatitis and HIV, those patients are being advised to get tested for...
Chronic Hepatitis B Virus Is Undertreated
FRIDAY, May 3, 2024 – Underassessment and undertreatment of chronic hepatitis B virus (HBV) is seen globally, according to a study published online May 1 in the Journal of Hepatology. Sahith ...
FDA Expands Indication for Gilead's Vemlidy (tenofovir alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
March 28, 2024 – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug...
U.S. Food and Drug Administration Approves Vemlidy (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Approval Expands on Previous FDA Approval of Vemlidy in Adults Living With This Chronic Liver Disease Efficacy and Safety of Once-Daily Vemlidy Demonstrated in Individuals 12 Years of Age and Older ...
Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults
BERKELEY, CA – (Marketwired) – November 9, 2017 – Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved Heplisav-B...
FDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir...
FDA Medwatch Alert: Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating
ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain...
FDA Medwatch Alert: Recombivax HB (Hepatitis B Vaccine (Recombinant)) Adult Formulation by Merck Sharp and Dohme Corp.: Recall - Potential For Cracked Vials
ISSUE: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck), initiated this voluntary recall due to the potential for a limited number of cracked vials to be present in the lot....